Investors interested in Medical Info Systems stocks are likely familiar with Inspire Medical Systems (INSP) and Hims & Hers Health, Inc. (HIMS) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate rev ...

Key Takeaways HIMS operates a consumer-first platform, integrating telehealth, prescriptions and pharmacy fulfillment.HIMS expands in diagnostics with Labs and early cancer detection, plus specialty care like GLP-1 therapies.Hims & Hers scales globally via acquisitions like Eucalyptus and expansion into Canada and Europe.Renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) is fundamentally built as a consumer-first digital health platform that uses technology to reconfigure how care is acc ...

Core Viewpoint - Hims & Hers has faced challenges in 2026, but a partnership with Novo Nordisk could revitalize its operations, particularly with the introduction of the Wegovy pill, potentially positioning the company for high growth by the end of 2026 [1]. Company Summary - Hims & Hers is expected to launch the Wegovy pill, which is anticipated to significantly impact its growth trajectory [1]. - The stock price of Hims & Hers was noted at 8.78% as of March 18, 2026, indicating market interest despite previous difficulties [1]. Industry Summary - The collaboration with Novo Nordisk highlights a strategic move within the healthcare sector, focusing on weight management solutions [1]. - The launch of Wegovy is seen as a pivotal moment for Hims & Hers, potentially transforming it into a high-growth stock by the end of 2026 [1].

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stock Market Casualties You Can’t Ignore Today. Hims & Hers fell by 8.86 percent on Friday to close at $22.02 apiece, as investors unloaded positions amid a combination of market pessimism and profit-taking, having soared by as much as 88 percent already this month. The company fell alongside the broader market, with the three major indices on Wall Street all slashing 1 to 2 percent of their value during the day. Meanwhile, investors took the opportu ...

It has been a wild ride for Hims & Hers (NYSE: HIMS) shareholders over the last few years. The stock is currently in a 65% drawdown from its highs, but up 50% in March, due to the telehealth platform's latest deal with a weight-loss drugmaker that was formerly suing it. Now, Hims & Hers is teaming up with its former enemies. Here are two S&P 500 index stocks to watch after this latest Hims & Hers stock move, and what it means for the future of the weight-loss market. Will AI create the world's first trill ...

Core Insights - Hims & Hers Health, Inc. (HIMS) is developing a consumer-focused digital health platform aimed at enhancing accessibility, personalization, and convenience in healthcare [2] - The company is expanding its digital healthcare ecosystem with new offerings such as Labs for tracking health markers and advanced diagnostics for early cancer detection [3][4] Group 1: Company Developments - Hims & Hers has introduced its Labs service, allowing users to track key health markers and receive doctor-developed action plans for proactive care [3][8] - The platform is expanding into advanced diagnostics, including a multi-cancer early detection test that screens for signals across various cancer types [3] - HIMS is broadening its treatment options, particularly in weight management, through collaborations with pharmaceutical partners [3] Group 2: Technology and Global Expansion - The company is investing in artificial intelligence (AI) to provide more personalized care at scale [4] - Hims & Hers is pursuing strategic acquisitions and partnerships to extend its digital healthcare model into new international markets [4] Group 3: Market Performance and Valuation - Hims & Hers shares have decreased by 28.6% over the past year, which is a better performance compared to the industry decline of 29.4% [7] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 1.9X, lower than the industry average of 3.4X and its five-year median of 2.6X [11] - The Zacks Consensus Estimate for HIMS' 2026 earnings per share suggests a flat performance compared to 2025 [9]

Core Viewpoint - The relationship between pharmaceutical giant Novo Nordisk and telehealth company Hims & Hers Health has evolved from collaboration to legal disputes, but a new agreement allows Hims & Hers to sell Novo Nordisk's GLP-1 drugs, which could benefit both companies and their investors [1][2]. Group 1: Agreement Details - Hims & Hers Health will now sell FDA-approved GLP-1 drugs, Ozempic and Wegovy, including the newly approved Wegovy pill, improving its market position [5]. - Previously, Hims & Hers was selling compounded versions of these drugs, which were not FDA-approved, posing a risk to its growth potential amid increasing demand for GLP-1 drugs [5]. Group 2: Company Performance - Novo Nordisk has reduced its sales guidance for the upcoming year due to competition, particularly from Eli Lilly's GLP-1 treatments and the trend of patients opting for compounded versions to save costs [6]. - The new agreement with Hims & Hers Health could enhance Novo Nordisk's growth rate moving forward [6]. Group 3: Stock Performance - Both Novo Nordisk and Hims & Hers Health have seen their stock prices decline over 20% this year, with Hims & Hers experiencing more volatility, including a drop of up to 55% at one point [7]. - Novo Nordisk, valued at nearly $170 billion, is considered a safer investment compared to Hims & Hers, which has a market cap of around $6 billion and lighter margins [7][8].

Core Viewpoint - Hims & Hers Health Inc. experienced a significant share price increase of 57.4% week-on-week, primarily due to a renewed partnership with Novo Nordisk and analysts upgrading their price targets for the stock [1]. Partnership and Strategy - Hims & Hers announced a new partnership with Novo Nordisk, which involves discontinuing the sale of compounded versions of Wegovy and Ozempic. The company will only provide access to its own GLP-1 if customer needs cannot be met with FDA-approved versions and if deemed clinically necessary by a provider [2]. Analyst Upgrades - Following the partnership announcement, Hims & Hers received upgraded price targets from three investment firms: Deutsche Bank raised its target to $28 from $25, Citigroup increased its target to $24 from $13.25, and Bank of America set a new target of $23, up from $12.50 [3]. - Citigroup and Bank of America also upgraded their ratings to "neutral" from "sell" and "underperform," respectively [4].

Core Insights - Retail investors have shown significant interest in five stocks this week, influenced by retail hype, earnings reports, AI discussions, and corporate news flow [1] Stock Summaries - **Oracle (ORCL)**: The stock is trading between $159 and $162, with a 52-week range of $118.86 to $345.72. It has risen 5.48% over the year but has fallen 45.53% in the last six months. The stock shows a weaker price trend across all time frames and has a poor value ranking according to Benzinga's Edge Stock Rankings [8] - **Hims & Hers (HIMS)**: Trading around $23 to $25, with a 52-week range of $13.74 to $70.43. The stock has declined by 29.47% over the year and 57.05% in the last six months. It has a weaker price trend in the medium and long terms but shows a strong trend in the short term, with a moderate growth ranking [8] - **Blue Owl Capital (OWL)**: The stock is trading between $8 and $10, with a 52-week range of $8.60 to $21.88. It has declined 54.61% over the year and 54.08% in the last six months. OWL has a weak price trend across all time frames and a poor value ranking [8] - **MicroStrategy (MSTR)**: Trading around $137 to $142, with a 52-week range of $104.17 to $457.22. The stock is down 47.69% over the year and 58.56% in the last six months. MSTR maintains a weaker price trend across all time frames according to Benzinga's Edge Stock Rankings [8] - **Tesla (TSLA)**: The stock is trading between $395 and $400, with a 52-week range of $214.25 to $498.83. It has advanced by 59.22% over the year but is down 0.23% in the last six months. TSLA shows a weak price trend in the short and medium terms but a strong trend in the long term, with a moderate quality ranking [8]

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 11 Best Day Trading Stocks to Buy Now. Investment bank Barclays discussed Hims & Hers Health, Inc. (NYSE:HIMS)’s shares on March 11th. It raised the share price target to $29 from $25 and kept an Overweight rating on the stock. Barclays commented that the fact that Hims & Hers Health, Inc. (NYSE:HIMS)’s shares had performed well after its agreement with Novo Nordisk indicated that the firm’s legal woes were behind it. Barclays added that the market appear ...